TipRanks on MSN

Altimmune’s IMPACT NASH trial completion puts pemvidutide back in the spotlight

Altimmune ($ALT) announced an update on their ongoing clinical study. Altimmune’s IMPACT trial, officially titled “A Phase 2, Multicenter, ...
TipRanks on MSN

Sino Biopharm’s oral psoriasis drug TQH3906 delivers biologic-like efficacy in phase II trial

Sino Biopharmaceutical ( ($HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for ...

Clywedog Therapeutics Announces Activation of All Centers and Patient Dosing in Multicenter, International Phase 1b Clinical Study of Balomenib in Type 2 Diabetes

The Phase 1b study is designed to evaluate the safety and tolerability of orally administered balomenib over a 28-day treatment period, followed by a post-treatment observation phase of up to ...